Santa Clara, Calif., July 21, 2016 — Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expanded its San Diego facility to create CrownBio’s U.S. Center of Excellence for Oncology, to support increasing demand for oncology research studies.
The enlarged 22,000-square-foot facility more than triples CrownBio’s original capacity at this site, adding multiple holding rooms and dedicated procedure and formulation space. The USDA-certified facilities, fitted with Biosafety Level 2 environmental controls, also allow for handling of viral agents for oncolytic virus studies.
“By expanding our U.S. Center of Excellence for Oncology, we have enhanced both our capabilities and capacity, to meet the increased demand for the types of oncology research critical to public health,” said Jean-Pierre Wery, Ph.D., CEO of CrownBio.
This expansion enables scientists to isolate and compartmentalize incoming projects, including separate suites for work with infectious agents. CrownBio’s immuno-oncology capabilities will be enlarged, with separate rooms dedicated to immunocompetent and immunodeficient models.
This expansion also improves CrownBio’s ability to minimize contamination risk, while protecting data integrity of the study.
“This expanded San Diego facility will enable CrownBio to continue to offer our clients the timelines and responsiveness they demand, and at the same time allow us to optimize resource and capacity management in the U.S.,” said Mike Prosser, CrownBio’s general manager of European and North American operations. “By creating a single Center of Excellence in North America, we can now deliver the highest quality research from a truly state-of-the art facility.”
For more information about CrownBio’s dedication to furthering oncology and metabolic disease research, visit www.crownbio.com.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...